Are you Dr. Bertolino?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 58 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
6362 144th Ave
Holland, MI 49423Phone+1 201-965-9573
Summary
- Dr. Arthur Bertolino, MD is a board certified dermatologist in Holland, Michigan. He is currently licensed to practice medicine in Michigan, Massachusetts, and Ohio.
Education & Training
NYU Grossman School of MedicineResidency, Dermatology, 1983 - 1985- NYU Grossman School of MedicineResidency, Internal Medicine, 1982 - 1983
- NYU Grossman School of MedicineResidency, Dermatology, 1981 - 1982
Johns Hopkins University School of MedicineInternship, Transitional Year, 1980 - 1981- Johns Hopkins University School of MedicineClass of 1980
Certifications & Licensure
MI State Medical License 2003 - 2026
NJ State Medical License 1987 - 2019
NY State Medical License 1981 - 2019
MD State Medical License 1980 - 2018
MA State Medical License 2003 - 2017
OH State Medical License 2001 - 2017- American Board of Dermatology Dermatology
Clinical Trials
- A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer Start of enrollment: 2017 Feb 09
Publications & Presentations
PubMed
- 255 citationsEfficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomi...Iain B. McInnes, Joachim Sieper, Juergen Braun, Paul Emery, Désirée van der Heijde
Annals of the Rheumatic Diseases. 2014-02-01 - 433 citationsAnti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trialDominique Baeten, Xenofon Baraliakos, Jürgen Braun, Joachim Sieper, Paul Emery
Lancet. 2013-11-23 - 1131 citationsSecukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trialWolfgang Hueber, Bruce E. Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch
Gut. 2012-12-01
Press Mentions
Innovation Pharmaceuticals Partnering Provides Momentum for Inflammatory Bowel Disease Programs, Targeting a Substantial and Prized Market with a Large Unmet Patient NeedOctober 14th, 2019
Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. For the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative ProctosigmoiditisJuly 22nd, 2019
Innovation Pharmaceuticals to Attend 2019 BIO International Convention, June 3-6May 29th, 2019- Join now to see all
